RaQualia Pharma (TSE:4579) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 08, 2026)


TSE:4579 RaQualia Pharma Inc TSE:4579
57 GF Score
Price 円468.00
GF Value 円961.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Float Percentage Of Total Shares Outstanding?

RaQualia Pharma TSE:4579 -2.70% 57 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 08, 2026. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, RaQualia Pharma's float shares is 0.00 Mil. RaQualia Pharma's total shares outstanding is 26.02 Mil. RaQualia Pharma's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, RaQualia Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, RaQualia Pharma's Institutional Ownership is 0.14%.

TSE:4579
57GF Score
RaQualia Pharma Inc TSE:4579
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

RaQualia Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/26.02
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
RaQualia Pharma (TSE:4579) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Float Percentage Of Total Shares Outstanding too high?
RaQualia Pharma's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
RaQualia Pharma's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score

Get the complete analysis for TSE:4579

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00
Price
円961.31
GF Value